News
New CCP e-Newsletter 2021
The first issue of our brand new online newsletter is available on https://phenogenomics.cz. We are delighted to share our recent achievements and updates on mouse phenogenomics, so from now on, the latest developments at CCP will be directly delivered to you via e-mail, with a dedicated website and interesting links for further reading. Enjoy reading… Read more
Season’s greetings and the best wishes for the New Year
We wish you all the best for the New Year and look forward to cooperating with you in 2022. Read more
CCP evaluated in the International peer-review of large research infrastructures in the Czech Republic in 2021
In the first half of 2021, the Ministry of Education, Youth and Sports organized an international peer-review of large research infrastructures in the Czech Republic, which results were published in December. The purpose of this evaluation was to obtain independent expert reviews about the performance of large research infrastructures. CCP confirmed its top level. According… Read more
Infrafrontier in the new ESFRI 2021 Roadmap
The updated ESFRI Roadmap was published this week. INFRAFRONTIER is mentioned as an example of ESFRI Research Infrastructures in response to emergencies, specifically to the covid-19 crisis. “INFRAFRONTIER rapidly evolved a broad portfolio of services to evaluate the potential of new anti-COVID-19 compounds and therapeutics on suitable humanized models as well as BSL3 laboratories for… Read more
CCP talk at final PATHBIO meeting
Radislav Sedlacek shared experience of the Czech Centre for Phenogenomics in preclinical development in his talk “Beyond standardized phenotyping pipeline: the path towards preclinical development” at the final PATHBIO meeting “Reproducibility and Translatability in Research: the Path forward”. The meeting took place on 3rd December, 2021 in Naples. The meeting was opened by a keynote… Read more
Sharing & archiving of genetically altered mice: opportunities for reduction and refinement
International experts on breeding, managing and archiving colonies gathered in the expert working group of the UK National Centre for the Replacement & Refinement & Reduction of Animals in Research has updated the document “Sharing & archiving of genetically altered mice: opportunities for reduction and refinement”. The updated document reflects how current best practices in… Read more
Three CCP members joined COST Actions
Jan Rozman joined the new COST Action CA20135 – Improving biomedical research by automated behaviour monitoring in the animal home-cage. The Action will assess the potential of these technologies, develop user guidelines and standard operating procedures and identify needs for further technological development. CCP will bring knowledge in preclinical testing in the stroke research field… Read more
Covid-19 mouse models available at CCP
Ace2 knock-out model A number of promising COVID-19 therapies is focused on targeting the Ace2 receptor. Thus, it is desired to evaluate: the potential of Ace2 blocking to prevent viral entry into the cells unwanted off-target effects caused by Ace2 deficiency. Ace2 deficient mutant mice provide an excellent tool for these types of experiments. Tmprss2… Read more
Register for CCP Conference 2021 now
Virtual, 16 – 17 September 2021 / Participation free of charge for all registered participants. Immunology & Infection Disease models Neurosciences Preclinical development KEYNOTE LECTURES Steve Brown, MRC Harwell Institute, United Kingdom – “Illuminating the dark genome: genome-wide approaches for understanding the genetic basis of disease” Yann Herault, Institut de Génétique et de Biologie Moléculaire… Read more
UPDATE: New jobs available in the CCP
Looking for an adventure of finding new phenotypes and good perspective for personal development? CCP welcomes applications for the following open positions: MALDI imaging researcher assistant / lab technician Research Specialist / Technical Specialist in Immunology Unit Head for Lung and Cardiovascular phenotyping For more detail about the positions please check our Career page Read more